Definium Therapeutics, Inc.

DT Pharma Inc. is a late-stage clinical biopharmaceutical company focused on developing new product candidates for brain health disorders. The company aims to develop accessible treatments by applying scientific methods to psychedelics. DT Pharma Inc. is building a pipeline of innovative product candidates that target neurotransmitter pathways important in brain health disorders. These include pharmaceutically optimized candidates derived from psychedelic and empathogen drug classes, such as DT120 (formerly MM120) and DT402 (formerly MM402), which are its lead product candidates. The company's first lead product candidate, DT120 ODT, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate. It is being developed to treat adults with generalized anxiety disorder (GAD) and major depressive disorder. In December 2023, DT Pharma Inc. reported positive topline results from its Phase 2b clinical trial of DT120 for GAD. The trial achieved its primary endpoint, showing statistically significant and clinically meaningful dose-dependent improvements on the Hamilton Anxiety Rating Scale ("HAM-A") compared to placebo at Week 4. In March 2024, the U.S. Food and Drug Administration ("FDA") granted breakthrough designation to the DT120 program for GAD. Also in March 2024, the company announced that its Phase 2b clinical trial of DT120 in GAD met its key secondary endpoint, with 12-week topline data demonstrating clinically and statistically significant durability of activity through Week 12. In September 2025, the full results from the Phase 2b clinical trial of DT120 in GAD were published in the Journal of the American Medical Association. In June 2024, DT Pharma Inc. completed its End-of-Phase 2 meeting with the FDA, supporting the progression of DT120 into pivotal trials for adults with GAD. The Phase 3 clinical program for DT120 ODT is expected to include two clinical trials: the Voyage study (DT120-300) and the Panorama study (DT120-301).